| Dr Joshua Quast, DO | |
|
10000 Telegraph Rd, Taylor, MI 48180-3330 | |
| (313) 375-7226 | |
| Not Available |
| Full Name | Dr Joshua Quast |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 10000 Telegraph Rd, Taylor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619606035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 5151015696 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua Quast, DO 10000 Telegraph Rd, Taylor, MI 48180-3330 Ph: (313) 375-7226 | Dr Joshua Quast, DO 10000 Telegraph Rd, Taylor, MI 48180-3330 Ph: (313) 375-7226 |
News Archive
Researchers at Weill Cornell Medical College have successfully tested their novel anti-cocaine vaccine in primates, bringing them closer to launching human clinical trials.
A new physical form of proteins developed by researchers at The University of Texas at Austin could drastically improve treatments for cancer and other diseases, as well as overcome some of the largest challenges in therapeutics: delivering drugs to patients safely, easily and more effectively.
Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.
› Verified 6 days ago
Dr. Sean Ronald Sellwood, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-295-5000 | |
Christine Davis, DO Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-295-5000 | |
Jungyoon Jung, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-295-5000 | |
Rachel Reeves, DO Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-375-7226 | |
Jessica Gustad, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-982-5150 | |
Dr. Juliet Irene Peck, MBBS Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 805-598-7184 | |
Dr. James Alexander Borges, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 10000 Telegraph Rd, Taylor, MI 48180 Phone: 313-375-7226 |